Bibliografías temáticas / EGFR / Libros

Libros sobre el tema "EGFR"

Siga este enlace para ver otros tipos de publicaciones sobre el tema: EGFR.
Autor: Grafiati
Publicado: 4 de junio de 2021
Última modificación: 6 de julio de 2024

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 50 mejores mejores libros para su investigación sobre el tema "EGFR".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore libros sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Haley, John D. y William John Gullick, eds. EGFR Signaling Networks in Cancer Therapy. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-356-1.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Cappuzzo, Federico. Guide to Targeted Therapies: EGFR mutations in NSCLC. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-03059-3.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

D, Haley John y Gullick William John, eds. EGFR Signaling Networks in Cancer Therapy / edited by John D. Haley, William John Gullick. New York, NY: Humana Press, 2008.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Rudzik, Nicholas James. A genetic analysis of the role of neuralized in the notch and EGFR pathways of Drosophila melanogaster. Ottawa: National Library of Canada, 1999.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Saki, Mohammad. Radiolabeling of anti-EGFR antibody, Cetuximab, overcomes the radiotherapy resistance of Cetuximab resistant head and neck cancer cells. [S.l: s.n.], 2014.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Faber, Anthony. Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC. Elsevier Science & Technology, 2022.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Faber, Anthony. Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC. Elsevier Science & Technology Books, 2021.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Patel, Harun M., Rahul Pawara y S. J. Surana. Third-Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems. Elsevier, 2018.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Patel, Harun M., Rahul Pawara y Sanjay J. Surana. Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems. Elsevier, 2018.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Schaeybroeck, Sandra Van. Egfr Activity As a Determinant of Response to Egfr-targeted Therapy. Leuven Univ Pr, 2006.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
11

Third Generation EGFR Inhibitors. Elsevier, 2019. http://dx.doi.org/10.1016/c2017-0-02893-8.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
12

Cappuzzo, Federico. Guide to Targeted Therapies : EGFR mutations in NSCLC: EGFR mutations in NSCLC. Adis, 2014.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
13

Haley, John D. y William John Gullick. EGFR Signaling Networks in Cancer Therapy. Humana, 2011.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
14

Haley, John D. y William John Gullick. EGFR Signaling Networks in Cancer Therapy. Humana Press, 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
15

Cappuzzo, Federico. Guide to Targeted Therapies: EGFR Mutations in NSCLC. Springer, 2014.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
16

Cappuzzo, Federico. Guide to Targeted Therapies: Egfr Mutations in Nsclc. Springer International Publishing AG, 2014.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
17

Hu, Shi. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies. Elsevier Science & Technology, 2022.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
18

Hu, Shi. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies. Elsevier Science & Technology Books, 2022.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
19

Herrington, William G., Aron Chakera y Christopher A. O’Callaghan. Chronic kidney disease. Editado por Patrick Davey y David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0163.

Texto completo
Resumen
Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, where the abnormalities have been present for >3 months and have implications for health. It is characterized by a reduced estimated glomerular filtration rate (eGFR) or other renal abnormalities. CKD is staged according to the eGFR or the degree of albuminuria. The KDIGO (Kidney Disease: Improving Global Outcomes) criteria for CKD is either an eGFR that is <60 ml/min 1.73 m−2 and has been present for >3 months, or one or more markers of kidney damage, when these have been present for >3 months.
Los estilos APA, Harvard, Vancouver, ISO, etc.
20

Ahn, Sun-Young Sarah. The involvement of EGF, EGFr, MSX1, PAX9 and LEF1 in EL mouse third molar hypodontia. 2004.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
21

Troncone, Giancarlo, Julia Rotow, Parneet Cheema y Pasquale Pisapia. Fast Facts: EGFR Exon 20 Insertion Mutations in NSCLC. Karger AG, S., 2022.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
22

Morris, Zachary Scott. Regulation of EGFR by the NF2 tumor supressor, Merlin. 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
23

Troncone, Giancarlo, Julia Rotow, Parneet Cheema y Pasquale Pisapia. Fast Facts: EGFR Exon 20 Insertion Mutations in NSCLC. Karger AG, S., 2022.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
24

Birle, Diana C. Interactions between inhibitors of mTOR and EGFR/ERK signaling in SiHa cervical carcinoma. 2004.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
25

Viloria-Petit, Alicia. The role of VEGF in tumor angiogenesis induced by EGFR-type oncogenic tyrosine kinases. 2003.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
26

D. Carlos L. Morales Gutiérrez. Valor Pronóstico Del Ca 19,9 y el Egfr Tisulares en la Supervivencia Del Carcinoma Colorrectal. Universidad Complutense de Madrid, Servicio de Publicaciones, 2005.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
27

Hodgkiss, Andrew. Introduction to cancer biology. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198759911.003.0001.

Texto completo
Resumen
A brief introduction to cancer biology, aimed at psychiatrists, is offered. Selective DNA transcription, the cell cycle, receptor tyrosine kinases, and cell signalling pathways are introduced, using the EGFR/RAS/MAPK pathway as an exemplar. The molecular pathology of oncogenesis is summarized, including discussion of oncogenes, tumour suppressor genes, and examples of driver mutations. The exploitation of such mutations in stratified medicine, using molecularly targeted agents, is mentioned. Finally, Hanahan and Weinberg’s six hallmarks of cancer are listed, adding angiogenesis and metastasis to the picture of oncogenesis.
Los estilos APA, Harvard, Vancouver, ISO, etc.
28

Bordás, Veronica. Development and analysis of a mathematical model integrating TGFα-EGFR trafficking and MAPK signaling in A431 cells. 2010.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
29

Preusser, Matthias, Gabriele Schackert y Brigitta G. Baumert. Metastatic brain tumours. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199651870.003.0019.

Texto completo
Resumen
Brain metastasis is a common clinical challenge in cancer patients, particularly those with lung cancer, breast cancer, and melanoma. The prognosis is poor, with median overall survival times measured in months for most patient populations. Established treatments include neurosurgical resection, radiotherapy (including stereotactic radiosurgery and stereotactic radiotherapy, whole-brain radiotherapy, and new radiation techniques), and supportive care measures. Recently, more and more targeted therapies such as EGFR inhibitors, HER2 antagonists, BRAF inhibitors, ALK inhibitors, and immune checkpoint inhibitors are demonstrating some efficacy in brain metastasis patients and should be considered in the clinical setting.
Los estilos APA, Harvard, Vancouver, ISO, etc.
30

Waldek, Stephen. Fabry disease. Editado por Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0338_update_001.

Texto completo
Resumen
Fabry disease is a rare X-linked lysosomal storage disorder in which deficiency of alpha-galactosidase A leads to accumulation of substrate, mostly globotriaosylceramide (Gb3), which causes a progressive, multiorgan disease affecting predominantly the kidneys, skin, heart, and nervous system. Painful peripheral (‘acral’) neuropathy is characteristic. Proteinuria and estimated glomerular filtration rate (eGFR) are strongly associated with risk of progression, but this may be reduced by treatment with angiotensin-converting enzyme inhibitors as well as by enzyme replacement therapy (ERT). ERT was approved in 2001; it improves pain and other neuropathic symptoms, and well-being, and has been proven to clear deposits of Gb3 from tissues, at variable speeds. There is limited randomized controlled trial data but protective effects have been proven for renal outcomes, death, and better outcomes in some other organ systems. Renal function may be protected if ERT is commenced before there is heavy proteinuria or substantial loss of GFR. It is recommended to start ERT as soon as the diagnosis is made in those with very low or absent enzyme. For those with intermediate levels it is recommended to commence treatment only when signs or symptoms appear. Proteinuria and eGFR give most information from a renal point of view, but renal biopsy is also useful for confirming the renal diagnosis and staging the disease as well as monitoring progress in selected cases. Management should include regular screening for complications including myocardial and neurological assessments. It is likely that registries will show progressive rises in median survival with this condition.
Los estilos APA, Harvard, Vancouver, ISO, etc.
31

Smith, David J. Eger... Kirmizi Kedi, 2016.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
32

Ede D. Szabó Ottó Kaiser. Eger. Kaiser Art Ltd., 2003.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
33

n/a y Alper Akcam. Eger. Tekin Yayinevi, 2015.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
34

Güner, Hafize Çinar. Eger. Nesin Yayinevi, 2021.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
35

Denyer-Green, Barry. EGLR 1994. Estates Gazette, 1995.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
36

Eglr 2008. Estates Gazette, 2008.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
37

Denyer-Green, Barry. EGLR 2004. Estates Gazette, 2005.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
38

Denyer-Green, Barry. EGLR 1993. Estates Gazette, 1994.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
39

Denyer-Green, Barry. EGLR 2004. Estates Gazette, 2004.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
40

Denyer-Green, Barry. EGLR 1993. Estates Gazette, 1993.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
41

Forman, Gayle. Eger Yasarsam. Pegasus, 2013.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
42

Denyer-Green, Barry. EGLR 1992. Estates Gazette, 1993.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
43

Watt, J. Muir. EGLR 1979. Estates Gazette, 1995.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
44

Watt, J. Muir. EGLR 1978. Estates Gazette, 1995.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
45

Watt, J. Muir. EGLR 1975. Estates Gazette, 1995.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
46

Ubhi, Navjit y Barry Denyer-Green. EGLR 2004. Estates Gazette, 2005.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
47

Denyer-Green, Barry. EGLR 2002. Estates Gazette, 2002.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
48

Denyer-Green, Barry. EGLR 2003. Estates Gazette, 2003.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
49

Denyer-Green, Barry. EGLR 2002. Estates Gazette, 2002.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
50

Denyer-Green, Barry. EGLR 1993. Estates Gazette, 1994.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
También puede estar interesado en las bibliografías sobre el tema "EGFR" para otros tipos de fuentes:
Artículos de revistas Tesis
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía